Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 2/20 | 0.46 |
| ▸ | ALB | P02768 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TRPV4 | Q9HBA0 | 3/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
| ▸ | EGLN2 | Q96KS0 | 5/20 | 0.34 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20912550 | 0.78 | TTR (0.52) | TTRALBMEN1KMT2ATRPV4 | |
| SCHEMBL30297979 | 0.78 | TTR (0.52) | TTRALBMEN1KMT2ATRPV4 | |
| SCHEMBL31485922 | 0.78 | MAP2K1 (0.40) | TTRALBMEN1KMT2AHTT | |
| SCHEMBL157603 | 0.78 | CES2 (0.42) | TTRALBMEN1KMT2ATRPV4 | |
| SCHEMBL30372844 | 0.77 | VCAM1 (0.56) | MEN1KMT2AVCAM1 | |
| SCHEMBL6649045 | 0.76 | TRPV4 (0.61) | TTRALBMEN1KMT2ATRPV4 | |
| SCHEMBL29710965 | 0.75 | TRPV4 (0.43) | MEN1KMT2ATRPV4CYP11B1CYP11B2 | |
| SCHEMBL14247428 | 0.75 | MEN1 (0.48) | TTRALBMEN1KMT2AHTT | |
| SCHEMBL8773853 | 0.75 | TTR (0.72) | TTRALBMEN1KMT2AHTT | |
| SCHEMBL198609 | 0.74 | TTR (0.52) | TTRALBMEN1KMT2ATRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12486449-B2 | Organic molecules for use in organic optoelectronic devices | SAMSUNG DISPLAY CO., LTD. (KR) | 2025-12-02 | — | — | US | disclosed |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2025-04-10 | — | — | US | disclosed |
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | ARDELYX, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-12122749-B2 | Heterocyclic compound and organic light-emitting device comprising same | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-10-22 | — | — | US | disclosed |
| CN-107531698-B | Fused bicyclic heteroaryl derivatives having activity as PHD inhibitors | 武田药品工业株式会社 | 2024-08-13 | — | — | CN | disclosed |
| EP-4363425-A1 | SMARCA DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2024-05-08 | — | — | EP | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023239645-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| CN-114634512-B | Compounds as inhibitors of bruton's tyrosine kinase, preparation method and medical application thereof | 江苏恒瑞医药股份有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-0391591-B1 | Pyrimidine derivative and liquid crystal composition incorporating the same | SEIKO EPSON CORP (JP) | 1994-06-15 | — | — | EP | disclosed |
| EP-0390329-B1 | Pyrimidine derivative | SEIKO EPSON CORP (JP) | 1993-12-01 | — | — | EP | disclosed |
| EP-0317175-B1 | PYRIMIDINE DERIVATIVES | SEIKO EPSON CORPORATION (JP) | 1993-09-22 | — | — | EP | disclosed |
| US-5200110-A | Electro-optical displays; heat resistance, dielectrics, low driving voltage, dielectrics | SEIKO EPSON CORPORATION (JP) | 1993-04-06 | — | — | US | disclosed |
| EP-0447565-A1 | 1,3-DIOXANE DERIVATIVE AND LIQUID-CRYSTAL COMPOSITION CONTAINING THE SAME | SEIKO EPSON CORPORATION (JP) | 1991-09-25 | — | — | EP | disclosed |
| US-5030382-A | Liquid crystals | SEIKO EPSON CORPORATION (JP) | 1991-07-09 | — | — | US | disclosed |
| EP-0391591-A2 | Pyrimidine derivative and liquid crystal composition incorporating the same | SEIKO EPSON CORPORATION (JP) | 1990-10-10 | — | — | EP | disclosed |
| EP-0390329-A1 | Pyrimidine derivative | SEIKO EPSON CORPORATION (JP) | 1990-10-03 | — | — | EP | disclosed |
| US-4883609-A | LIQUID CRYSTALS | SEIKO EPSON CORPORATION (JP) | 1989-11-28 | — | — | US | disclosed |
| EP-0317175-A2 | Pyrimidine derivatives | SEIKO EPSON CORPORATION (JP) | 1989-05-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209088-B2 | Hormone receptor modulators for treating metabolic conditions and disorders | NR1H4, FXR1, GLP1R | TTR 2475/4885ALB 1992/4885MEN1 343/4885 |
| US-20250170248-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | TTR 4658/4885ALB 4771/4885MEN1 2085/4885 |
| US-12486449-B2 | Organic molecules for use in organic optoelectronic devices | OR10J3, OR51E2, OCIAD2 | TTR 999/4885ALB 2056/4885MEN1 2119/4885 |
| US-12122749-B2 | Heterocyclic compound and organic light-emitting device comprising same | CCND2, CCND1, CRY1 | TTR 3921/4885ALB 3039/4885MEN1 438/4885 |
| US-20250115608-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS | NR1H4, FXR1, GLP1R | TTR 2475/4885ALB 1992/4885MEN1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.